Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2016-06-14 Earnings Release
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Maiden Preliminary Results for FY15
Earnings Release Classification · 100% confidence The document explicitly states it announces the 'Maiden Preliminary Results for the Year Ended 31 December 2015'. It contains key financial highlights (Net loss for FY2015, IPO details, cash position) and operational updates, which are characteristic of an initial release of periodic financial results. Although it is comprehensive, the structure and timing (released on June 14, 2016, for the year ended Dec 31, 2015) suggest it is the primary announcement of the annual performance, fitting the definition of an Annual Report (10-K) or, more commonly for non-US companies or preliminary releases, an Earnings Release (ER) or Interim Report (IR) if it were quarterly. Since it covers the full year and includes a Chairman's statement and CEO overview, it is the primary annual financial disclosure. Given the options, and the fact that it is a preliminary announcement of *annual* results, it aligns best with the comprehensive nature of an Annual Report (10-K) or, if it's the initial press release summarizing the full year, an Earnings Release (ER). However, the depth of the Chairman's and CEO's statements, covering strategy, pipeline (PT20), and the recent IPO, suggests it is more than just the 'key highlights only' of an ER. Since it is a preliminary announcement of *annual* results, and the document is quite long (56k chars), it is likely the content that would form the basis of the 10-K or is the official annual results release. Given the context of a preliminary announcement of *annual* results, 'ER' (Earnings Release) is often used for the initial public release of annual figures before the full statutory filing, but '10-K' is reserved for the official SEC filing. Since this is a UK company (LSE:STX) announcing 'preliminary results', and it is not explicitly a quarterly report (IR), the closest fit for a comprehensive annual summary announcement is ER, or potentially AR if it were just the audit section. Given the content is the full results summary, ER is the most appropriate classification for the initial public announcement of annual performance. FY 2015
2016-06-14 English
Notice of results and change of accounting date
Regulatory Filings Classification · 98% confidence The document is a short announcement (2393 characters) filed via RNS (indicated by 'RNS Number : 9687S' and 'This information is provided by RNS'). The primary content announces a change in the accounting reference date and explicitly states when the maiden annual results will be reported ('The Company will report its audited annual accounts for a twelve month period to 31 December 2015 on 14 June 2016'). Since the document is an announcement about the *timing* and *publication* of future reports rather than the report itself, and it is a regulatory filing, it fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K or IR, nor is it a general miscellaneous filing (RNS) because RPA is more specific for this context.
2016-03-23 English
[change-account-reference-date-company-previous-shortened] made_up_date=2016-09-30, new_date=2015-12-31
Regulatory Filings
2016-03-21 English
Grant of Share Awards
Remuneration Information Classification · 99% confidence The document is an official announcement filed via RNS (RNS Number : 7706R) on March 11, 2016. The content explicitly details the 'Grant of Share Awards' (options over ordinary shares) to directors under the Long Term Incentive Plan (LTIP). This type of transaction, involving personal share dealings or grants to directors/executives, falls under the category of Director's Dealing (DIRS). Although it involves shares, it is a specific grant/award notification rather than a general share repurchase (POS) or a general capital change (SHA). Since it specifically reports transactions by directors, DIRS is the most appropriate classification.
2016-03-11 English
First Day of Dealings on AIM
Share Issue/Capital Change Classification · 99% confidence The document is an official announcement released via RNS (RNS Number : 2755Q) on February 26, 2016. The content explicitly announces the 'First Day of Dealings on AIM' following a successful placing and subscription, raising gross proceeds of £32.5 million. This describes a significant capital raising and listing event. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes, which corresponds to the 'Capital/Financing Update' (CAP) definition. Although it is an RNS announcement, the core subject matter is a capital event, making CAP more specific than the general RNS fallback.
2016-02-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.